Quit Genius, a digital clinic for treating multiple addictions, has raised an oversubscribed $64M Series B funding round co-led by Kinnevik and Atomico, with participation from Series A investors Octopus Ventures, Triple Point Ventures and Startup Health.

Quit Genius is a digital clinic for treating nicotine, alcohol and opioid addictions. Built on the evidence-based practice of Medication-Assisted Treatment (MAT), Quit Genius combines virtual behavioral therapy with approved medication and connected devices to help employers tackle the high cost of addiction in the workplace while improving the lives of their employees.